pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
651
stories
May 9, 26
The OncFive: Top Oncology Articles for the Week of 5/3
onclive
May 8, 26
Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT
onclive
May 8, 26
Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
onclive
May 8, 26
FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
onclive
May 8, 26
UT MD Anderson Shares Latest Research Breakthroughs
onclive
May 8, 26
Former FDA leaders, pharma speak out on mifepristone
stat
May 8, 26
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
biopharma dive
May 8, 26
Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL
onclive
May 7, 26
Dr Sznol on Optimal Treatment Sequencing in Melanoma
onclive
May 7, 26
Dr Mauro on the Significance of Alternative TKI Formulations in CML
onclive
May 7, 26
Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC
onclive
May 7, 26
FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease
onclive
May 7, 26
ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies
onclive
May 7, 26
Entrada shares dive as Duchenne results disappoint
biopharma dive
May 7, 26
STAT+: More political interference at the FDA?
stat
May 7, 26
STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
stat
May 7, 26
Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
endpoints
May 7, 26
STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
stat
May 6, 26
Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
onclive
May 6, 26
Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC
onclive
May 6, 26
Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
onclive
May 6, 26
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
onclive
May 6, 26
STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review
stat
May 6, 26
Dr Sznol on Biomarkers of Response in Metastatic Melanoma
onclive
May 6, 26
Why the FDA is authorizing fruit-flavored vapes
stat
May 6, 26
ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
onclive
May 6, 26
Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
onclive
May 6, 26
Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?
stat
May 5, 26
Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
onclive
May 5, 26
Dr Pant on Managing Toxicities With Daraxonrasib in PDAC
onclive
← prev
page 20 of 22
next →
